Hypoxia-activated prodrugs in cancer therapy: progress to the clinic (Q37707385)

22 August 2017

1 reference

title

Hypoxia-activated prodrugs in cancer therapy: progress to the clinic (English)

1 reference

22 August 2017

0 references

1

William A Denny

1 reference

PubMed ID

20222798

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

419-428

1 reference

22 August 2017

3

1 reference

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

22 August 2017

1 reference

21 January 2018

Capecitabine: a review

1 reference

Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis

21 January 2018

1 reference

Hypoxic regulation of mRNA expression.

21 January 2018

1 reference

Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase

21 January 2018

1 reference

3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.

21 January 2018

1 reference

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs

21 January 2018

1 reference

Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.

21 January 2018

1 reference

Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9

21 January 2018

1 reference

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer

21 January 2018

1 reference

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

21 January 2018

1 reference

Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase

21 January 2018

1 reference

The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

21 January 2018

1 reference

Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry

21 January 2018

1 reference

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

21 January 2018

1 reference

Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).

21 January 2018

1 reference

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study

21 January 2018

1 reference

Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study

21 January 2018

1 reference

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

21 January 2018

1 reference

Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro

21 January 2018

1 reference

Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides

21 January 2018

1 reference

Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction

21 January 2018

1 reference

DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).

21 January 2018

1 reference

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase

21 January 2018

1 reference

Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria

21 January 2018

1 reference

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells

21 January 2018

1 reference

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

21 January 2018

1 reference

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

21 January 2018

1 reference

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

21 January 2018

1 reference

Tirapazamine: a novel agent targeting hypoxic tumor cells

21 January 2018

1 reference

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors

21 January 2018

1 reference

Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures

21 January 2018

1 reference

Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity

21 January 2018

1 reference

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

21 January 2018

1 reference

Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells

21 January 2018

1 reference

Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines

21 January 2018

1 reference

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

21 January 2018

1 reference

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia

21 January 2018

1 reference

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

21 January 2018

1 reference

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

21 January 2018

1 reference

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

21 January 2018

1 reference

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

21 January 2018

1 reference

Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers

21 January 2018

1 reference

Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding

21 January 2018

1 reference

EF5 binding and clinical outcome in human soft tissue sarcomas

21 January 2018

1 reference

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

21 January 2018

1 reference

Metabolism of oxazaphosphorines

21 January 2018

1 reference

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.1

1 reference

22 August 2017

1 reference

PubMed ID

20222798